# US 2001/0024807 A1 · Expression vectors, transfection systems, and method of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0024807 A1
- Document ID: US20010024807A1
- Status: Published application
- Kind: A1
- Application number: 09/748,061
- Filed: 2000-12-22
- Published: 2001-09-27
- Earliest claimed: 1999-11-01
- Assignees: Chiron Corporation
- Inventors: Michael Innis; Elizabeth M. Scott
- Web page: https://patentgrep.com/patent/US20010024807A1

## CPC

- C12N 15/907: {in mammalian cells}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 9/003: {Dihydrofolate reductase [DHFR] (1.5.1.3)}
- C12N 9/1205: {Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases}
- C12N 15/85: for animal cells
- C12N 2800/107: for mammalian
- C12N 2800/40: Systems of functionally co-operating vectors
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Expression vectors and transfection systems providing high expression of a desired polypeptide are provided. Also provided are methods of using the expression vectors and transfection systems and mammalian cells modified by these compositions and methods.

## Claims

### Claim 1

An expression vector comprising:
(a) a first polynucleotide encoding a first, crippled, selectable marker;
(b) a second polynucleotide encoding a heterologous polypeptide of interest; and
(c) a third polynucleotide encoding a second, amplifiable selectable marker.

### Claim 2 (depends on 1)

The expression vector of claim 1, wherein the first, crippled selectable marker is selected from the group consisting of a sequence coding for a neomycin resistance gene having a mutation at amino acid residue 182, a sequence coding for a neomycin resistance gene having a mutation at amino acid residue 261 and a sequence coding for a neomycin resistance gene having mutations at amino acid residues 182 and 261.

### Claim 3 (depends on 1)

The expression vector of claim 1, wherein the third polynucleotide encodes for dihydrofolate reducatase (dhfr).

### Claim 4 (depends on 1)

The expression vector of claim 1, wherein the heterologous polypeptide of interest is selected from the group consisting of CAB-2, CAB-4, uPAR, VEGF-D and a viral protein.

### Claim 5 (depends on 1)

The expression vector of claim 1, wherein the heterologous pdlypeptide of interest is a viral glycoprotein.

### Claim 6

A plasmid selected from the group consisting of pESN1dhfr, pESN2dhfr, pESN3dhfr, pneoldhfr5′del, pneo3dhfr5′del, pneo2dhfr5′del, and pdhfr3′del.

### Claim 7

A plasmid designated pESN1dhfr.

### Claim 8

A plasmid designated pESN2dhfr.

### Claim 9

A plasmid designated pESN3dhfr.

### Claim 10

A plasmiddesignatedpneo1dhfr5′del.

### Claim 11

A plasmid designated pneo3dhfr5′del.

### Claim 12

A plasmid designated pneo2dhfr5′del.

### Claim 13

A plasmid designated pdhfr3′del.

### Claim 14 (depends on 1)

A method for producing a polypeptide of interest in a host cell, comprising
(a) introducing an expression vector according to claim 1 into suitable host cells;
(b) selecting host cells which express the first and second selectable markers under conditions that select for stably integrated expression vectors;
(c) growing the stably-transfected host cells under conditions which favor expression of the polypeptide of interest, and
(d) isolating the polypeptide of interest.

### Claim 15 (depends on 6)

A method for producing a polypeptide of interest in a host cell, comprising
(a) introducing an expression vector according to claim 6 into suitable host cells;
(b) selecting host cells which express the first and second selectable markers under conditions that select for stably integrated expression vectors;
(c) growing the stably-transfected host cells under conditions which favor expression of the polypeptide of interest, and
(d) isolating the polypeptide of interest.

### Claim 16 (depends on 14)

The method of claim 14 wherein the polypeptide of interest is selected from the group consisting of CAB-2, CAB-4, uPAR, VEGF-D and a viral protein.

### Claim 17 (depends on 14)

The method of claim 14, wherein the polypeptide is a viral protein.

### Claim 18 (depends on 14)

The method of claim 14, wherein the host cell is a mammalian or insect cell.

### Claim 19 (depends on 14)

A host cell line that produces a polypeptide of interest, wherein said polypeptide is produced according to the method of claim 14.

### Claim 20

A transfection system comprising
(a) a first construct comprising, in a suitable backbone, a sequence encoding a first selectable marker and a sequence encoding a second selectable marker, wherein the second selectable marker contains at least one disabling mutation in its coding sequence; and
(b) a second construct comprising, in a suitable backbone, a polynucleotide sequence of interest and a sequence encoding a third selectable marker, wherein the third selectable marker is the same selectable marker as the second selectable marker except that the third selectable marker contains at least one disabling mutation that is in a different region of the coding sequence than the disabling mutation in said second selectable marker.

### Claim 21 (depends on 20)

The transfection system of claim 20, wherein said first selectable marker encodes for antibiotic resistance.

### Claim 22 (depends on 20)

The transfection system of claim 20, wherein said first selectable marker encodes neomycin phosphotransferase II.

### Claim 23 (depends on 22)

The transfection system of claim 22, wherein the neomycin phosphotransferase II is functionally impaired.

### Claim 24 (depends on 20)

The transfection system of claim 20, wherein the second selectable marker in the first construct is disabled by at least one mutation in the 5′ coding region and the third selectable marker in the second construct is disabled by at least one different mutation in the 3′ coding region.

### Claim 25 (depends on 24)

The transfection system of claim 24, wherein said mutations are point mutations.

### Claim 26 (depends on 20)

The transfection system of claim 20, wherein said mutations are deletions.

### Claim 27 (depends on 20)

The transfection system of claim 20, wherein said second and third selectable markers encode dihydrofolate reductase (DHFR).

### Claim 28 (depends on 20)

The transfection system of claim 20, wherein the constructs are plasmids.

### Claim 29 (depends on 28)

The transfection system of claim 28, wherein the plasmid further comprises
(c) first, second, and third promoters operably linked to said first and second selectable markers and said transgene, respectively;
(d) sequences encoding polyadenylation sites operably linked to said first and second selectable markers and said transgene; and
(e) sequence encoding origins of replication operably linked to said first, second selectable markers and said transgene.

### Claim 30 (depends on 29)

The transfection system of claim 29, wherein said first promoter is selected from the group consisting of a CMV promoter, an RSV promoter or an SV-40 early promoter.

### Claim 31 (depends on 29)

The transfection system of claim 29, wherein said second promoter is selected from the group consisting of a CMV promoter, an RSV promoter or an SV-40 early promoter.

### Claim 32 (depends on 29)

The transfection system of claim 29, wherein said third promoter is selected from the group consisting of a CMV promoter, an RSV promoter or an SV-40 early promoter.

### Claim 33 (depends on 29)

The transfection system of claim 29, wherein said first and third promoters are CMV promoters and said second promoter is an SV40 early promoter.

### Claim 34

A method for producing a mammalian cell line for expression of a selected polynucleotide sequence, comprising
(a) introducing into a selected mammalian cell, having a genome, a first construct comprising a sequence encoding a first selectable marker and a sequence encoding a second selectable marker, wherein the second selectable marker contains at least one disabling mutation in its coding sequence,
(b) selecting for a mammalian cell expressing the first selectable marker, wherein said first construct stably integrates into the genome;
(c) introducing into the mammalian cell a second construct comprising a polynucleotide sequence of interest and a sequence encoding a third selectable marker, wherein the third selectable marker is the same selectable marker as the second selectable marker except that the third selectable marker contains at least one disabling mutation that is in a different region of the coding sequence than the disabling mutation in said second selectable marker; and
(d) selecting for a mammalian cell expressing a functional product encoded by the second selectable marker, wherein the functional product is encoded by a sequence produced by a recombination event between said second and third selectable markers, and the resulting mammalian cell is capable of expressing the selected polynucleotide sequence.

### Claim 35 (depends on 34)

The method of claim 34, wherein said selected polynucleotide sequence encodes a polypeptide.

### Claim 36 (depends on 35)

The method of claim 35, wherein expressing the selected polynucleotide sequence results in expression of the polypeptide.

### Claim 37 (depends on 34)

A mammalian cell produced by the method of claim 34.

### Claim 38

A method for producing a polypeptide of interest in a host mammalian cell, said method comprising:
(a) introducing into said cell, having a genome, a first construct comprising a sequence encoding a first selectable marker and a sequence encoding a second selectable marker, wherein the second selectable marker contains at least one disabling mutation in its coding sequence;
(b) selecting for a mammalian cell expressing the first selectable marker, wherein said first construct stably integrates into the genome;
(c) introducing into the mammalian cell a second construct comprising a polynucleotide sequence encoding the polypeptide of interest and a sequence encoding a third selectable marker, wherein the third selectable marker is the same selectable marker as the second selectable marker except that the third selectable marker contains at least one disabling mutation that is in a different region of the coding sequence than the disabling mutation in said second selectable marker;
(d) selecting for a mammalian cell expressing a functional product encoded by the second selectable marker, wherein the functional product is encoded by a sequence produced by a recombination event between said second and third selectable markers, and the resulting mammalian cell is capable of expressing the polypeptide of interest; and
(e) culturing the mammalian cell under conditions to produce the polypeptide of interest.

### Claim 39 (depends on 38)

The method of claim 38 wherein said first selectable marker encodes for neomycin resistance.

### Claim 40 (depends on 38)

The method of claim 38, wherein said second and third selectable markers encode dhfr.

### Claim 41 (depends on 38)

The method of claim 38, wherein introduction of said constructs into said cells is by electroporation.

### Claim 42 (depends on 38)

The method of claim 38, wherein introduction of said constructs into said cells is by calcium phosphate transfection.

### Claim 43 (depends on 38)

A mammalian cell line that produces a polypeptide of interest, wherein said cell line is produced according to the method of claim 38.
